Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2015

01-09-2015 | Research Article

Long non-coding RNA BANCR regulates growth and metastasis and is associated with poor prognosis in retinoblastoma

Authors: Shizheng Su, Jian Gao, Tao Wang, Ju Wang, Hong Li, Zhen Wang

Published in: Tumor Biology | Issue 9/2015

Login to get access

Abstract

Recent evidence shows that BRAF-activated non-coding RNA (BANCR) acts as a critical role in the proliferation and metastasis in malignant melanoma and lung cancer; however, little is known about the significance of lncRNA BANCR in retinoblastoma. The purpose of our study is to explore the role of lncRNA BANCR in retinoblastoma clinical samples and cell lines. The expression of lncRNA BANCR was measured in 60 retinoblastoma samples and normal retina samples by using RT-PCR. The effects of lncRNA BANCR on cell proliferation, migration, and invasion were also explored. In our results, lncRNA BANCR is overexpressed in retinoblastoma tissues and cell lines and is associated with tumor size, choroidal invasion, and optic nerve invasion. Moreover, patients with high levels of lncRNA BANCR expression had poorer survival than those with lower levels of lncRNA BANCR expression. Multivariate analysis showed that increased lncRNA BANCR expression was a poor independent prognostic factor for retinoblastoma patients. Furthermore, knocking down lncRNA BANCR expression significantly suppressed the retinoblastoma cell proliferation, migration, and invasion in vitro. In conclusion, lncRNA BANCR plays a significant role in retinoblastoma aggressiveness and prognosis and may act as a promising target for therapeutic strategy and prognostic prediction.
Literature
1.
Villegas VM, Hess DJ, Wildner A, Gold AS, Murray TG. Retinoblastoma. Curr Opin Ophthalmol. 2013;24:581–8.CrossRefPubMed
2.
Abramson DH. Retinoblastoma in the 20th century: past success and future challenges the Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2005;46:2683–91.CrossRefPubMed
3.
Melamud A, Palekar R, Singh A. Retinoblastoma. Am Fam Physician. 2006;73:1039–44.PubMed
4.
Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21:203–12.CrossRefPubMed
5.
Varan A, Kiratli H, Aydin B, Tarlan B, Poyraz CB, Akyuz C, et al. The treatment of retinoblastoma with four-drug regimen including cisplatin, etoposide, vincristine, and cyclophosphamide. Pediatr Hematol Oncol. 2012;29:529–37.CrossRefPubMed
6.
7.
Bowman RJ, Mafwiri M, Luthert P, Luande J, Wood M. Outcome of retinoblastoma in east Africa. Pediatr Blood Cancer. 2008;50:160–2.CrossRefPubMed
8.
Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M. Childhood cancer survival trends in Europe: a Eurocare working group study. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:3742–51.CrossRef
9.
Lin P, O’Brien JM. Frontiers in the management of retinoblastoma. Am J Ophthalmol. 2009;148:192–8.CrossRefPubMed
10.
Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–9.CrossRefPubMed
11.
12.
13.
14.
Flockhart RJ, Webster DE, Qu K, Mascarenhas N, Kovalski J, Kretz M, et al. BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. Genome Res. 2012;22:1006–14.CrossRefPubMedPubMedCentral
15.
Sun M, Liu XH, Wang KM, Nie FQ, Kong R, Yang JS, et al. Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. Mol Cancer. 2014;13:68.CrossRefPubMedPubMedCentral
16.
Guo Q, Zhao Y, Chen J, Hu J, Wang S, Zhang D, et al. BRAF-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition. Oncol Lett. 2014;8:869–75.PubMedPubMedCentral
17.
Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:2334–40.CrossRef
18.
19.
Martin J, Bryar P, Mets M, Weinstein J, Jones A, Martin A, et al. Differentially expressed miRNAs in retinoblastoma. Gene. 2013;512:294–9.CrossRefPubMed
20.
Wang J, Wang X, Li Z, Liu H, Teng Y. Microrna-183 suppresses retinoblastoma cell growth, invasion and migration by targeting LRP6. FEBS J. 2014;281:1355–65.CrossRefPubMed
21.
Lei Q, Shen F, Wu J, Zhang W, Wang J, Zhang L. MiR-101, downregulated in retinoblastoma, functions as a tumor suppressor in human retinoblastoma cells by targeting EZH2. Oncol Rep. 2014;32:261–9.PubMed
22.
Li R, Zhang L, Jia L, Duan Y, Li Y, Bao L, et al. Long non-coding RNA BANCR promotes proliferation in malignant melanoma by regulating MAPK pathway activation. PLoS One. 2014;9, e100893.CrossRefPubMedPubMedCentral
23.
Wang Y, Guo Q, Zhao Y, Chen J, Wang S, Hu J, et al. BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. Oncol Lett. 2014;8:1947–52.PubMedPubMedCentral
24.
Jiang W, Zhang D, Xu B, Wu Z, Liu S, Zhang L, et al. Long non-coding RNA BANCR promotes proliferation and migration of lung carcinoma via MAPK pathways. Biomed Pharmacother. 2015;69:90–5.CrossRefPubMed
Metadata
Title
Long non-coding RNA BANCR regulates growth and metastasis and is associated with poor prognosis in retinoblastoma
Authors
Shizheng Su
Jian Gao
Tao Wang
Ju Wang
Hong Li
Zhen Wang
Publication date
01-09-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3413-3

Other articles of this Issue 9/2015

Tumor Biology 9/2015 Go to the issue

Commentary

Reply to: “in vivo post-contrast 1H-MRS evaluation of malignant and benign breast lesions: a meta-analysis”

Retraction Note

Retraction Note to: Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis

Retraction Note

Retraction Note to: Relationship between VEGF protein expression and lymph node metastasis in papillary thyroid carcinoma among Asians: a meta-analysis

Research Article

Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients

Research Article

ALDH1 might influence the metastatic capability of HeLa cells

Erratum

Erratum to: Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits